Edition:
United States

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

23.59USD
27 Jun 2017
Change (% chg)

$-1.31 (-5.26%)
Prev Close
$24.90
Open
$24.90
Day's High
$25.20
Day's Low
$23.58
Volume
1,153,903
Avg. Vol
1,112,024
52-wk High
$25.20
52-wk Low
$7.43

EXEL.OQ

Chart for EXEL.OQ

About

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's... (more)

Overall

Beta: 1.93
Market Cap(Mil.): $7,283.56
Shares Outstanding(Mil.): 292.51
Dividend: --
Yield (%): --

Financials

  EXEL.OQ Industry Sector
P/E (TTM): 2,324.93 242.00 19.11
EPS (TTM): 0.01 -- --
ROI: 1.47 -8.00 -5.00
ROE: -- -10.45 -4.24

BRIEF-Ipsen and Exelixis announce IRC confirms cabozantinib significantly improved progression-free survival compared to sunitinib

* IPSEN SA - IPSEN AND ITS PARTNER EXELIXIS ANNOUNCE INDEPENDENT RADIOLOGY COMMITTEE REVIEW CONFIRMS RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

Jun 19 2017

BRIEF-Exelixis announces Independent Radiology Committee review confirms results from CABOSUN

* Exelixis announces independent radiology committee review confirms results from cabosun, the phase 2 trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

Jun 19 2017

BRIEF-Exelixis announces initiation of early-stage trial of combination drug

* Exelixis Inc announces initiation of Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors Source text for Eikon: Further company coverage:

Jun 12 2017

BRIEF-Exelixis Q1 earnings per share $0.05

* Exelixis announces first quarter 2017 financial results and provides corporate update

May 01 2017

BRIEF-Exelixis further reduces indebtedness by repaying Silicon Valley Bank term loan

* Exelixis further reduces indebtedness by repaying silicon valley bank term loan

Mar 29 2017

BRIEF-Exelixis' cabozantinib granted orphan drug designation

* Exelixis' cabozantinib granted orphan drug designation for the treatment of hepatocellular carcinoma

Mar 06 2017

BRIEF-Exelixis announces clinical trial collaboration with Roche

* Exelixis announces clinical trial collaboration with Roche to evaluate cabozantinib and atezolizumab in locally advanced or metastatic solid tumors

Feb 27 2017

BRIEF-Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab

* Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab in refractory metastatic urothelial carcinoma and other genitourinary tumors

Feb 17 2017

BRIEF-Exelixis and Takeda enter into exclusive licensing agreement

* Exelixis and Takeda enter into exclusive licensing agreement to commercialize and develop novel cancer therapy cabozantinib in Japan

Jan 30 2017

BRIEF-Genentech withdraws counterclaim against Exelixis in JAMS arbitration

* Update on dispute between Exelixis and Genentech, a member of the Roche group

Jan 09 2017

More From Around the Web

Competitors

Earnings vs. Estimates